Dea Nagy
Overview
Explore the profile of Dea Nagy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagle R, Algotar A, Cortez C, Smith K, Jones C, Sathyanarayana U, et al.
Prostate
. 2013 May;
73(11):1233-40.
PMID: 23653096
Background: This study examines the combined effect of two common genetic alterations, ERG and PTEN, in prostate carcinoma progression. Methods: Prostate tissue from 90 patients having unilateral capsular penetrating lesions,...
2.
Svensson M, LaFargue C, MacDonald T, Pflueger D, Kitabayashi N, Santa-Cruz A, et al.
Lab Invest
. 2010 Oct;
91(3):404-12.
PMID: 20975660
Prostate cancer is a clinically heterogeneous and multifocal disease. More than 80% of patients with prostate cancer harbor multiple geographically discrete cancer foci at the time of diagnosis. Emerging data...
3.
Park K, Tomlins S, Mudaliar K, Chiu Y, Esgueva R, Mehra R, et al.
Neoplasia
. 2010 Jul;
12(7):590-8.
PMID: 20651988
TMPRSS2-ERG gene fusions occur in 50% of prostate cancers and result in the overexpression of a chimeric fusion transcript that encodes a truncated ERG product. Previous attempts to detect truncated...
4.
Jiang H, Couto L, Patarroyo-White S, Liu T, Nagy D, Vargas J, et al.
Blood
. 2006 Jul;
108(10):3321-8.
PMID: 16868252
In a clinical study of recombinant adeno-associated virus-2 expressing human factor IX (AAV2-FIX), we detected 2 impediments to long-term gene transfer. First, preexisting anti-AAV neutralizing antibodies (NABs) prevent vector from...
5.
Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan C, et al.
Blood
. 2006 Mar;
108(1):107-15.
PMID: 16522813
Hemophilia A, a deficiency of functional coagulation factor VIII (FVIII), is treated via protein replacement therapy. Restoring 1% to 5% of normal blood FVIII activity prevents spontaneous bleeding, making the...
6.
Oiwa Y, Eberling J, Nagy D, Pivirotto P, Emborg M, Bankiewicz K
Front Biosci
. 2003 Sep;
8:a155-66.
PMID: 12957824
Monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have been widely used as animal models of Parkinson's disease (PD). Depending on the method of administration different PD models can be developed. Systemic (iv,...
7.
Scallan C, Liu T, Parker A, Patarroyo-White S, Chen H, Jiang H, et al.
Blood
. 2003 Aug;
102(12):3919-26.
PMID: 12893764
Using separate adeno-associated viral 2 (AAV2) vectors to deliver the heavy and light chains of factor VIII (FVIII) we have overcome the packaging limitations of AAV, achieving phenotypic correction of...
8.
Scallan C, Lillicrap D, Jiang H, Qian X, Patarroyo-White S, Parker A, et al.
Blood
. 2003 May;
102(6):2031-7.
PMID: 12738670
Gene therapy for hemophilia A requires efficient delivery of the factor VIII gene and sustained protein expression at circulating levels of at least 1% to 2% of normal. Adeno-associated viral...